Lior Zangi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5340910/publications.pdf

Version: 2024-02-01

29 papers	2,440 citations	361413 20 h-index	501196 28 g-index
30 all docs	30 docs citations	30 times ranked	3714 citing authors

#	Article	IF	Citations
1	Therapeutic Delivery of Pip4k2câ€Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart. Advanced Science, 2021, 8, 2004661.	11.2	14
2	Direct reprogramming induces vascular regeneration post muscle ischemic injury. Molecular Therapy, 2021, 29, 3042-3058.	8.2	21
3	In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy. Methods in Molecular Biology, 2021, 2158, 281-294.	0.9	8
4	Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery. Pharmaceutics, 2021, 13, 1675.	4.5	33
5	Lung-derived HMGB1 is detrimental for vascular remodeling of metabolically imbalanced arterial macrophages. Nature Communications, 2020, 11, 4311.	12.8	29
6	Modified mRNA as a Therapeutic Tool for the Heart. Cardiovascular Drugs and Therapy, 2020, 34, 871-880.	2.6	30
7	Specific Modified mRNA Translation System. Circulation, 2020, 142, 2485-2488.	1.6	18
8	Delivery of Modified mRNA in a Myocardial Infarction Mouse Model. Journal of Visualized Experiments, 2020, , .	0.3	3
9	Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration. Circulation, 2020, 141, 1249-1265.	1.6	147
10	Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction. Circulation, 2020, 141, 916-930.	1.6	84
11	Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. Nature Nanotechnology, 2020, 15, 398-405.	31.5	42
12	Optimization of 5â€² Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury. Molecular Therapy - Methods and Clinical Development, 2020, 17, 622-633.	4.1	26
13	Optimizing Modified mRNA InÂVitro Synthesis Protocol for Heart Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 14, 300-305.	4.1	34
14	mRNA-Based Protein Replacement Therapy for the Heart. Molecular Therapy, 2019, 27, 785-793.	8.2	101
15	Cardiac Sca-1⁺Cells Are Not Intrinsic Stem Cells for Myocardial Development, Renewal, and Repair. Circulation, 2018, 138, 2919-2930.	1.6	37
16	Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Molecular Therapy - Nucleic Acids, 2018, 13, 133-143.	5.1	49
17	Synthetic MicroRNAs Stimulate Cardiac Repair. Circulation Research, 2017, 120, 1222-1223.	4.5	6
18	Modified <scp>mRNA</scp> as a therapeutic tool to induce cardiac regeneration in ischemic heart disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2017, 9, e1367.	6.6	32

#	Article	IF	Citations
19	Optimizing Cardiac Delivery of Modified mRNA. Molecular Therapy, 2017, 25, 1306-1315.	8.2	84
20	Synthesis of Modified mRNA for Myocardial Delivery. Methods in Molecular Biology, 2017, 1521, 127-138.	0.9	20
21	Cover Image, Volume 9, Issue 1. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2017, 9, e1383.	6.6	0
22	Insulin-Like Growth Factor 1 Receptor-Dependent Pathway Drives Epicardial Adipose Tissue Formation After Myocardial Injury. Circulation, 2017, 135, 59-72.	1.6	74
23	Synthetic Chemically Modified mRNA (modRNA): Toward a New Technology Platform for Cardiovascular Biology and Medicine. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a014035-a014035.	6.2	45
24	Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA. Stem Cell Research, 2014, 13, 693-704.	0.7	26
25	Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nature Medicine, 2014, 20, 616-623.	30.7	733
26	How to make a cardiomyocyte. Development (Cambridge), 2014, 141, 4418-4431.	2.5	126
27	Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nature Biotechnology, 2013, 31, 898-907.	17.5	528
28	Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Research, 2013, 23, 1172-1186.	12.0	89
29	Gene Therapy for Heart Disease: Modified mRNA Perspectives. , 0, , .		0